Blog

Biobanking Market Outlook

The biobanking market size was valued at USD 72.1 billion in 2023, driven by the increased genomic research activities aimed at discovering innovative therapeutic interventions across the globe. The market is expected to grow at a CAGR of 6.89% during the forecast period of 2024-2032, with the values likely to rise from USD 76.9 billion in 2024 to USD 131.1 billion by 2032.

Biobanking: Introduction

Biobanking is a pivotal component in modern biomedical research, providing a systematic method for the collection, storage, and management of biological samples such as blood, tissue, and DNA. These biorepositories play a critical role in advancing our understanding of diseases, enabling the development of personalized medicine, and fostering innovations in diagnostics and therapeutics. By maintaining high-quality, well-annotated specimens, biobanks support large-scale genomic studies, biomarker discovery, and epidemiological research. As the field evolves, biobanking is becoming increasingly integral to the success of clinical trials and translational research, ensuring that valuable biological resources are preserved for future scientific breakthroughs.

Get a Free Sample Report with Table of Contents: https://www.expertmarketresearch.com/reports/biobanking-market/requestsample

Key Trends in the Global Biobanking Market

Key trends in the global biobanking market include:

1. Expansion of Precision Medicine Initiatives: The rise of precision medicine and personalized healthcare approaches is driving demand for high-quality biospecimens in biobanks. Biobanks play a crucial role in collecting, storing, and analysing biological samples linked to clinical and genomic data, facilitating research on individualized treatment strategies and targeted therapies for various diseases.
2. Adoption of Automation and Robotics: The integration of automation and robotics in biobanking operations is improving sample processing efficiency, data accuracy, and sample integrity. Automated systems for sample retrieval, storage, and retrieval reduce manual handling errors, minimize contamination risks, and enhance sample traceability, thereby optimizing biobank workflows and ensuring sample quality.
3. Emphasis on Standardization and Quality Assurance: There is a growing focus on standardization and quality assurance measures in biobanking practices to ensure the reproducibility and reliability of research findings. Guidelines such as the International Society for Biological and Environmental Repositories (ISBER) Best Practices promote harmonized procedures for sample collection, processing, storage, and data management, fostering confidence in biobank resources among researchers and regulatory agencies.
4. Integration of Omics Technologies: Biobanks are increasingly integrating omics technologies, including genomics, transcriptomics, proteomics, and metabolomics, to enhance the characterization and analysis of biological samples. Multi-omics approaches enable comprehensive profiling of molecular signatures and biomarkers associated with disease progression, treatment response, and patient outcomes, facilitating translational research and precision medicine applications.
5. Expansion of Disease-Specific Biobanks: Disease-specific biobanks are being established to support research on specific medical conditions, such as cancer, cardiovascular disease, neurodegenerative disorders, and rare diseases. These specialized biobanks collect comprehensive clinical and molecular data from patient cohorts, enabling targeted investigations into disease etiology, progression, and therapeutic interventions.
6. Utilization of Artificial Intelligence (AI) and Data Analytics: The integration of artificial intelligence (AI) and data analytics in biobanking operations enables advanced data mining, pattern recognition, and predictive modelling to derive insights from large-scale biomedical datasets. AI-driven algorithms facilitate biomarker discovery, patient stratification, and drug target identification, accelerating biomedical research and drug development efforts.
7. Collaboration and Data Sharing Initiatives: Collaborative networks and data sharing initiatives are promoting interdisciplinary research collaborations and maximizing the utility of biobank resources. Consortia such as the Global Alliance for Genomics and Health (GA4GH) facilitate data harmonization, interoperability, and ethical data sharing practices among biobanks, research institutions, and industry partners, fostering scientific discoveries and translational applications.
8. Regulatory and Ethical Considerations: Regulatory compliance and ethical considerations are paramount in biobanking to ensure patient privacy, informed consent, and adherence to legal requirements governing human subject research. Biobanks must adhere to national and international regulations, such as the General Data Protection Regulation (GDPR) in Europe and the Health Insurance Portability and Accountability Act (HIPAA) in the United States, to safeguard participant rights and data security.

Biobanking Market Segmentation

Market Breakup by Material

• Population-based Biobanks
• Disease-based Biobanks
• Academic Biobanks
• Hospital-based Biobanks
• Commercial Biobanks

Market Breakup by Sample Type

• Blood Products
• Human Tissues
• Nucleic Acids
• Cell Lines
• Biological Fluids
• Others

Market Breakup by Application

• Drug Discovery and Development
• Personalized Medicine
• Regenerative Medicine
• Clinical Research
• Forensics
• Others

Market Breakup by Ownership

• Public Biobanks
• Private Biobanks
• Hybrid Biobanks

Market Breakup by Source

• Human Biobanks
• Animal Biobanks
• Plant Biobanks

Market Breakup by End User

• Biopharmaceutical Companies
• Research and Academic Institutes
• Hospitals
• Contract Research Organizations (CROs)
• Others

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Read Full Report with Table of Contents: https://www.expertmarketresearch.com/reports/biobanking-market

Biobanking Market Overview

North America: North America holds a significant share in the biobanking market, driven by factors such as advanced healthcare infrastructure, robust research and development activities, and high demand for personalized medicine and precision healthcare. The presence of leading biobanks, academic research institutions, and pharmaceutical companies further contributes to market growth in this region.

Europe: Europe is a prominent market for biobanking, characterized by extensive biomedical research, well-established regulatory frameworks, and growing emphasis on translational medicine and precision oncology. Countries like Germany, the UK, and France are key contributors to market growth, with a strong focus on biobank infrastructure development, data harmonization, and collaborative research initiatives.

Asia Pacific: The Asia Pacific region is witnessing rapid growth in the biobanking market, fueled by factors such as increasing investment in healthcare infrastructure, rising prevalence of chronic diseases, and growing awareness about personalized medicine and genomic research. Countries like China, Japan, and India are key markets in the region, with expanding biobank networks, government initiatives, and industry partnerships driving market expansion.

Latin America: Latin America is experiencing steady growth in the biobanking market, driven by improving healthcare access, rising research funding, and increasing adoption of precision medicine approaches. Countries like Brazil, Mexico, and Argentina are key contributors to market growth, with a focus on biobank accreditation, data sharing, and capacity building in biomedical research.

Middle East and Africa: The Middle East and Africa region are emerging markets for biobanking, with increasing government investments in healthcare infrastructure, expanding biopharmaceutical industry, and rising prevalence of chronic diseases. Countries like Saudi Arabia, UAE, and South Africa are key markets in the region, with a focus on enhancing biobank capabilities, research collaborations, and biotechnology innovation.

Biobanking Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. is a leading global provider of scientific instrumentation, equipment, reagents, and services across the life sciences, healthcare, and industrial sectors. With a comprehensive portfolio of products and solutions, Thermo Fisher serves researchers, clinicians, and industrial professionals worldwide. The company’s offerings include laboratory instruments, analytical technologies, consumables, and software for applications ranging from biotechnology and pharmaceuticals to environmental analysis and clinical diagnostics. Thermo Fisher is committed to enabling scientific breakthroughs, improving patient outcomes, and driving innovation in fields such as genomics, proteomics, cell biology, and drug discovery, advancing scientific research and healthcare globally.

• Brooks Automation, Inc.

Brooks Automation, Inc. is a leading provider of automation and cryogenic solutions for various industries, including semiconductor manufacturing, life sciences, and healthcare. With headquarters in the United States, the company offers a wide range of products and services, including robotic systems, semiconductor manufacturing equipment, sample management solutions, and bioprocessing technologies. Brooks Automation serves customers worldwide, helping them improve productivity, efficiency, and quality in their manufacturing and research processes. The company’s innovative solutions address the evolving needs of its diverse customer base, driving advancements in technology, healthcare, and scientific research.

• Qiagen N.V.

Qiagen N.V. is a leading global provider of sample and assay technologies for molecular diagnostics, applied testing, and academic research. With headquarters in the Netherlands and operations spanning over 35 countries, Qiagen offers a diverse portfolio of molecular testing solutions, including sample preparation, assay technologies, and bioinformatics tools. The company’s products enable researchers and healthcare professionals to analyze biological samples and genetic information for applications such as infectious disease testing, oncology diagnostics, and personalized medicine. Qiagen’s commitment to innovation, quality, and customer satisfaction has established it as a trusted partner in advancing molecular biology and improving patient outcomes worldwide.

• Tecan Group Ltd.

Tecan Group Ltd. is a leading Swiss provider of laboratory automation and instrumentation solutions for the life sciences industry. With a history spanning over four decades, Tecan specializes in the design, development, and manufacturing of automated liquid handling systems, laboratory robotics, and detection instruments used in genomics, proteomics, drug discovery, and clinical diagnostics. The company’s innovative platforms enable scientists and researchers to streamline workflows, increase productivity, and accelerate scientific discoveries. Tecan’s comprehensive portfolio of products and services, combined with its global presence and commitment to customer satisfaction, positions it as a trusted partner in laboratory automation and scientific innovation.

• Hamilton Company

Hamilton Company is a global leader in the design and manufacture of precision liquid handling solutions, laboratory automation systems, and process analytics. With over 60 years of experience, Hamilton provides innovative products and services to the life sciences, biotechnology, pharmaceutical, and healthcare industries. The company’s portfolio includes pipettes, automated liquid handling workstations, sensors, and bioprocess equipment, known for their reliability, accuracy, and versatility. Hamilton’s commitment to quality, innovation, and customer satisfaction has established it as a trusted partner for laboratory and process automation needs worldwide, driving advancements in research, drug discovery, and diagnostics.

Other key players in the market include Chart Industries, Inc., PHC Holdings Corporation, Becton, Dickinson and Company (BD), Merck KGaA, Panasonic Healthcare Holdings Co., Ltd., STEMCELL Technologies Inc., Lifenet Health, Promega Corporation, Greiner Bio-One International GmbH, Lonza Group AG.